You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget

    SBC: DOTY SCIENTIFIC, INC.            Topic: NIA

    ? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Aminoglycosides with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: NIAID

    PROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. ARCHER- An Extremely Fast Medical Radiation Dose Computing Software

    SBC: VIRTUAL PHANTOMS INC            Topic: NIBIB

    DESCRIPTION provided by applicant The goal of this project is to develop a commercial software package for rapid Monte Carlo based dose computation in imaging and radiation therapy The product takes advantage of a desktop parallel computer equipped with emerging hardware originally developed gaming and high performance computing The project is motivated by the fact that the market is ripe for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Development and in vitro validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Development of an Antigen Capture Assay for Babesia microti

    SBC: Biopeptides, Corp            Topic: NIAID

    DESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. DRUG DISCOVERY PLATFORM FOR PROTEIN ARGININE METHYLTRANSFERASE INHIBITORS

    SBC: CH3 BIOSYSTEMS, LLC            Topic: 300

    Project Summary Abstract The long term objective of this project is the generation of a universal drug discovery platform based on protein arginine methylation mechanisms involved in human disease The importance of protein arginine methylation in the context of human disease has become clear in the last few years with the realization that protein arginine methyltransferases and the target prot ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Enabling Nanomembrane-Based Biomolecule and Nanoparticle Separations

    SBC: Simpore Inc.            Topic: 400

    DESCRIPTION provided by applicant The global market for nanoparticles NP in biotechnology drug development and drug delivery was estimated to be $ B for and is expected to reach more than $ B by The two most active areas of product development are NPs for drug delivery and for in vivo imaging In these applications it is often critical that he outer surfaces of NPs are functiona ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Engineering stem cells to make mucopolysaccharidosis IIIB

    SBC: Phoenix Nest Inc.            Topic: 107

    DESCRIPTION provided by applicant Sanfilippo disease type B also called mucopolysaccharidosis type III or MPS III is a devastating neuro degenerative genetic disorder of childhood that is fatal There is no cure or effective treatment MPS IIIB is caused by the lack of a lysosomal enzyme called NAGLU alpha N acetylglucosaminidase that is required to degrade heparan sulfate glycosaminoglyca ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Evaluation of TRB-N0224, a Proprietary Chemically-Modified Curumin, for the Treat

    SBC: TRAVERSE BIOSCIENCES, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): Traverse Biosciences Inc. is a pre-clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host-modulation of pathologically unrestrained matrix metalloproteinases (MMPs) and pro-inflammatory cytokines. The company's lead drug candidate, TRB-N0224, is a proprie ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government